Apogenix - APG101
We produced a 6-minute computer animation film on the mode of action of APG101 for Apogenix. Apogenix´ lead drug candidate APG101 is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an lgG antibody. APG101 is being developed for the treatment of solid tumors and malignant hematological diseases and has been evaluated in the treatment of glioblastoma and myelodysplastic syndromes (MDS).
The primary focus of the mode of action 3D animation film is the interaction between the CD95 ligand and the CD95 receptor, depending on the target cell (immune cell or tumor cell), induces either apoptotic cell death or invasive growth of cells. Consequently, APG101 has a dual mechanism of action.